Several clinical trials on monoclonal antibodies targeting programmed cell death ligand protein 1 (PD-L1), programmed cell death protein 1 (PD-1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have been or are currently being conducted for SCLC. This evidence concerns the gene CTLA4 and small cell lung carcinoma.